In overweight individuals with T2D (1704 participants), metformin reduces the risk of diabetes-related endpoints and is associated with fewer hypoglycemic periods and less weight gain than individuals receiving insulin or sulfonylureas [142]. Here, INS is linked to type 2 diabetes mellitus.